Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
$9.09M Sell
285,333
-182,433
-39% -$5.75M 0.4% 71
2017
Q1
$15.2M Buy
467,766
+453,451
+3,168% +$14.3M 0.74% 30
2016
Q4
$441K Sell
14,315
-82,573
-85% -$2.52M 0.04% 401
2016
Q3
$3.11M Sell
96,888
-49,328
-34% -$1.65M 0.18% 155
2016
Q2
$4.88M Sell
146,216
-18,977
-11% -$606K 0.28% 105
2016
Q1
$4.64M Buy
+165,193
New +$4.72M 0.32% 80
2015
Q4
Sell
-189,093
Closed -$5.63M 1003
2015
Q3
$5.63M Buy
+189,093
New +$6.06M 0.34% 92
2014
Q3
Sell
-288,299
Closed -$8.12M 943
2014
Q2
$8.12M Buy
+288,299
New +$8.22M 0.67% 26
2014
Q1
Sell
-25,754
Closed -$748K 830
2013
Q4
$748K Buy
+25,754
New +$750K 0.1% 229
2013
Q3
Sell
-184,688
Closed -$4.91M 614
2013
Q2
$4.91M Buy
+184,688
New +$5.1M 0.73% 18

Other funds holding PFE

Airain Ltd's PFE Position: Q2 2017 in Review

Airain Ltd reduced its Pfizer (PFE) stake by 39% in Q2 2017, selling an estimated $5.75M and leaving 285,333 shares worth $9.09M. The position accounts for 0.4% of the portfolio, ranked #71.

Airain Ltd first reported a position in PFE in Q2 2013 and has held it in 10 quarters since. The position peaked at $15.2M in Q1 2017. 2,049 funds tracked by Wall St. Rank hold PFE as of Q2 2017.

  • Airain Ltd held 285,333 shares of Pfizer worth $9.09M as of Q2 2017.
  • Airain Ltd sold 182,433 Pfizer shares in Q2 2017, an estimated $5.75M.
  • Pfizer made up 0.4% of Airain Ltd's portfolio in Q2 2017, its #71 holding.
  • Airain Ltd first reported a position in Pfizer in Q2 2013 and has held it in 10 quarters since.
  • Airain Ltd's Pfizer position peaked at $15.2M in Q1 2017.
  • 2,049 funds tracked by Wall St. Rank held Pfizer as of Q2 2017.

Based on Airain Ltd's 13F filing for Q2 2017, filed 8 Aug 2017.